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PREDICTORS OF CERVICAL CANCER 
INPATIENT ADMISSION COSTS BY STAGE
Berg GD, Chattopadhyay SK
Centers for Disease Control and Prevention (CDC), Atlanta, 
GA, USA
OBJECTIVES: The objectives were to obtain inpatient
admission cost distributions of cervical cancer by stage of
the disease and to identify significant predictors of cost.
METHODS: 1559 inpatient admission records for the
period 1994–1997 were obtained from MedStat’s private
insurance databases. Costs were measured by total pay-
ments. Probability densities of cost were calculated non-
parametrically for each stage. Regression analyses of cost
per stage were conducted using both nonparametric and
ordinary least squares (OLS) procedures. RESULTS: The
95% quantile of cost ranged from $12,748 for LSIL
(low-grade squamous intraepithelial lesions) to $44,505
for Stage IV cervical cancer. The OLS results show that
Health Maintenance Organizations (HMO) and Point of
Service (POS) plan types have significantly lower costs
than the comprehensive coverage plan (P  0.05) for all
five stages of cervical cancer. The largest difference was
seen in Stage IV with savings of $10,964 for HMO and
$11,544 for POS both compared to the comprehensive
coverage plan. Nonparametric regression analysis con-
firms this finding of statistically significant lower costs
for HMO and POS for all stages except HMO in Stage 2/3
and POS in Stage IV. CONCLUSIONS: It is not clear if
and to what extent the cost advantages of HMO and
POS relative to the comprehensive coverage plan com-
promise the quality of care. The information from the
study may be useful for predicting future costs of treat-
ment for cervical cancer. This may also help policy-makers
in the economic evaluation of cervical cancer screening
programs by providing benchmark values of treatment
cost savings made possible because of earlier detection of
cervical cancer.
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APPLICATION OF PHARMACOECONOMICS 
AND OUTCOMES RESEARCH ON DECISION-
MAKING PATTERNS BY 
MEDICAL ONCOLOGISTS
Sarpong DF, Jamero DJ, Ball CK
Xavier University, College of Pharmacy, New Orleans, LA, 
USA
The economic burden of cancer is considerable and of
growing concern. The direct medical cost of cancer care
in the US is estimated to be $100 billion per year, about
10% of all health care expenditures, which currently ex-
ceed $1 trillion annually. OBJECTIVES: The two objec-
tives of this research were to assess the extent of use of
pharmacoeconomics and outcomes research in making
therapeutic decisions by oncologists and to determine the
degree of variation in the pattern of therapeutic decision-
making of oncologists. METHOD: A 35-item survey in-
strument was administered by mail to Louisiana regis-
tered medical oncologists. The instrument was designed
to collect data on the demographics, application of phar-
macoeconomic tools and outcomes research (PEOR) to
practice, and decision-making patterns in response to a
clinical case. RESULTS: The oncologists’ mean length of
practice was 15.7 years. The percentages of respondents
applying PEOR measures in the decision of therapy
were as follows: drug cost (66.7%), cost of therapy fail-
ure (40%), pharmaco-/health economic tools (53.3%),
adverse events due to the drug(s) (86.7%), quality of life
(93.3%), and patients’ satisfaction (86.7%). The percent-
age of respondents who chose cyclophosphamide/doxo-
rubicin for first line, a taxane (docetaxel or paclitaxel)
for second line and vinorelbine for third line of therapy
were 46.7%, 66.7% and 46.2%, respectively. The per-
centages of inappropriate choice of anti-emetics for first,
second and third lines of therapy were 15.4%, 54.5%
and 38.5%, respectively. CONCLUSION: The study sug-
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gests that though oncologists use economic tools in their
choice of therapy, the extent of use is lower than ex-
pected; and the choice of therapy varied more with the
first and third lines of therapy.
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COST-EFFECTIVENESS OF EARLY DETECTION 
AND PREVENTION OF COLORECTAL CANCER 
BY SCREENING WITH FECAL OCCULT
BLOOD TESTS
Parson RE, Baker JT
Beckman Coulter, Inc., Primary Care Diagnostics, Palo Alto, 
CA, USA
Colorectal cancer (CRC), the second leading cause of
cancer deaths in the US, can be detected in its early
stages. Detection and removal of adenomas can prevent
CRC. Early detection of CRC by screening asymptomatic
populations with fecal occult blood tests (FOBTs) can
significantly reduce mortality and morbidity. OBJEC-
TIVE: The purpose of this analysis was to measure out-
comes when FOBTs are used as the primary screening
tools. METHODS: A cost-effectiveness model was devel-
oped for 10 years of annual serial screening. Assumptions
for the fixed cohort population were for an initial popu-
lation of 100,000 with 0.33% prevalence of CRC,
5.64% prevalence of adenomas (1 cm), 2.91% annual
conversion rate of adenomas to CRC, and an annual inci-
dence rate for adenomas of 0.31%. Two FOBTs were
evaluated in this analysis: Hemoccult (HO), and Hemoc-
cult SENSA (HOS). A decision-analytic model was used
to evaluate testing modalities, test positivity rates, pro-
gram compliance, treatment options and surveillance reg-
imens. Test performance statistics were obtained from
published clinical trials and related healthcare data. RE-
SULTS: Summary of Model Outcomes Compared to a
No Testing Scenario:
CONCLUSION: Cost-effective screening of asymptom-
atic populations can be achieved with either FOBT. HOS,
however, has better sensitivity than HO in detecting ade-
nomas and CRC. This results in greater prevention of
CRC and lower treatment and terminal care costs that fa-
vorably impact the $/LYG estimate.
FOBT
Adenomas
Detected
CRC
Prevented
CRC Deaths
Prevented
$ (000)/Life Year
Gained (LYG)
HO 2,016 304 193 $32
HOS 3,439 603 303 $25
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COST-EFFECTIVENESS OF GENETIC TESTING 
IN HEREDITARY NON-POLYPOSIS 
COLORECTAL CANCER
Henderson LB1,2, Scheuner MT1, Ofman JJ1,2
1Cedars Sinai Medical Center, Los Angeles, CA, USA; 2Zynx 
Health, Inc., Beverly Hills, CA, USA
Hereditary non-polyposis colorectal cancer (HNPCC) is
a cancer susceptibility syndrome characterized by in-
creased risk for colorectal cancer (CRC). Genetic testing
for HNPCC can risk-stratify family members. Those
lacking inherited susceptibility can avoid costly and fre-
quent colonoscopic surveillance. OBJECTIVE: Evaluate
the cost-effectiveness of a genetic testing strategy for a
family member at risk for inheriting susceptibility to
HNPCC-related CRC. METHODS: A decision analytic
model simulated health and economic outcomes. A hypo-
thetical cohort of 20 year-old consultants from HNPCC
kindreds progressed through the model. We assumed that
surveillance prevents CRC, and that patients averaged a
life expectancy of 80 years. The genetic testing strategy
included relevant mutation analysis with and without
screening a family member’s tumor tissue for microsatel-
lite instability (MSI) and immunohistochemical (IHC)
staining for the MLH1 and MSH2 gene products. Pa-
tients testing negative for a familial mutation underwent
surveillance as recommended by the American Cancer
Society, and those positive as recommended by the Inter-
national Collaborative Group for high-risk patients.
Probability estimates were derived from a systematic re-
view of the MEDLINE and HEALTSTAR databases.
Cost estimates were derived from the Medicare 1999
Physician Fee Schedule—Area 18. Sensitivity analyses
were performed on all estimates. The outcome was cost-
per-strategy to prevent CRC. RESULTS: The genetic test-
ing strategy yielded an average savings of $869.73 per
patient. Its cost-effectiveness persisted over a wide range
of probability and cost variables. The genetic testing
strategy resulted in 67% fewer invasive, endoscopic pro-
cedures. CONCLUSION: Both costs and procedures for
CRC surveillance and prevention are substantially re-
duced for at-risk individuals from an HNPCC kindred
who participate in a strategy that begins with genetic
testing.
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COST-EFFECTIVENESS OF RITUXIMAB IN 
RELAPSED, REFRACTORY, LOW-GRADE 
NON-HODGKIN’S LYMPHOMA
Cattaneo MJ, Nichol MB
Department of Pharmaceutical Economics and Policy, 
University of Southern California, School of Pharmacy, Los 
Angeles, CA, USA
Low Grade Non-Hodgkin’s Lymphoma (LGNHL) is an
indolent form of NHL with a median survival of four to
eleven years. This survival is dependent on the respon-
